Chris Scotto DiVetta’s Post

Read more about Michael C. Muelly, M.D.'s perspectives on IMVARIA's new project with Mayo Clinic in AI digital biomarkers in oncology! "Mayo Clinic will combine its large datasets for training algorithms and will utilize the IMVARIA Digital Biomarker Platform, which allows clinicians to develop regulatory-grade digital biomarkers months instead of years, providing them with tools for data ingestion, management, model development, regulatory documentation production, and the entire regulatory-grade MLOps lifecycle." https://lnkd.in/gQtSgrDa

AI-powered personalized cancer therapies can be tailored to optimize their effectiveness, reduce toxicity, adapt dosing schedules, and design combination therapy approaches. However, the process of translating these precision cancer therapies to patients currently faces significant waiting times for approval in the US and even longer timelines in the EU. Optimistically, developing new regulatory approaches with ethical implications and creating appropriate test platforms for surveillance will accelerate the process. #AI #precisionmedicine #translationalmedicine #regulatorysystem #enableplatforms

I just discovered an insightful publication in Cancer Medicine on the crucial role of communication in precision oncology between patients and healthcare professionals. It's a compelling dive into the challenges and best practices that can truly make a difference in patient care. It is highly recommended for anyone involved in healthcare to check it out and contribute to the ongoing discussion for better patient outcomes.   🔗 https://lnkd.in/dg5xtRKa #PrecisionOncology #PatientCare #HealthcareCommunication

"Equipping oncologists with the tools that reflect the depth of their field is not just about keeping pace – it’s about setting new standards of care," writes Sagran Moodley. As the oncology landscape continues to evolve, with updates to disease understanding, treatment methodologies, and biomarker research, using oncology-specific EHRs can help oncologists deliver the best possible care. Read more in this article on Answers Media Network. #EHR #Oncology #Biomarkers

𝐓𝐫𝐚𝐧𝐬𝐥𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐚𝐧𝐝 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐁𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫 Discovery and Validation await to be 𝐒𝐭𝐫𝐞𝐚𝐦𝐥𝐢𝐧𝐞𝐝/𝐒𝐭𝐚𝐧𝐝𝐚𝐫𝐢𝐳𝐞𝐝. Lack of standardization in biomarker testing processes, despite the availability of electronic health record solutions, contributes to clinician burden and may increase risk of delays in receipt of testing results; therefore, efforts to streamline ordering processes may benefit health systems.

The American Society of Clinical Oncology (ASCO) Annual Meeting is a premier gathering of #oncology professionals worldwide. Discover how our latest research sets the new standards in oncology, focusing on AI-driven diagnostics and personalized medicine. We have 3 abstracts accepted. One will be presented as a poster, and the others will be published online. 🧬 Prediction of oncogene mutation status in non-small cell lung cancer leveraging radiomics from CT scans: A systematic review and meta-analysis with a special focus on artificial-intelligence-based methods. 🧬 Unleashing deep features and radiomics to enhance best overall response prediction to immunotherapy in advanced non-small cell lung cancer    Please stop by our poster! Highlight Presentation by our VP of AI, Dr Ana Jimenez Pastor:  🧬 Overall survival prediction and risk stratification in patients with neuroblastoma through machine learning in the large multi-institutional PRIMAGE cohort. Our models provide superior risk stratification and survival predictions by leveraging a combination of clinical, molecular, and MR radiomics data.   We are excited to engage with the global oncology community to advance these technologies further. Find more about us here 👉 https://bit.ly/44J2sB5 #ASCO24

AI & Precision Medicine: A Game Changer for Pancreatic Cancer Exciting news for pancreatic cancer patients! AI is teaming up with precision medicine to identify unique patient signatures, leading to targeted therapies. This translates to: 👉 Smarter Treatment Plans: Doctors can identify the most effective options, minimizing unnecessary interventions and easing patient burden. 👉 Improved Outcomes: This breakthrough is paving the way for better treatment results and potentially, higher survival rates. Want to dive deeper? Check out the full article here: https://ow.ly/5szI50QOA6f #pancreaticcancer #precisionmedicine #ai #healthcare #futureofmedicine

Last month, Avestria led Clarified Precision Medicine's Seed round. This month, we're telling you why we invested in Clarified in the first place. This new "Under the Microscope" blog post from Avestria's Eva Epker covers the advantages of genomically-informed precision oncology treatments, the current challenges patients face in receiving those treatments, and the way that Clarified can help fill those gaps. Read more about why we invested in Clarified right here: https://lnkd.in/gZMEgKQn April Lynch Rajni Natesan, MD, MBA #healthcare #investment #precisiononcology #precisionmedicine #oncology #genomictesting

Unveiling the nuances of precision medicine in prostate cancer, this article underscores the pivotal role clinical biomarkers play in tailoring personalized treatment plans. For those deeply immersed in the healthcare domain, this insightful read sheds light on cutting-edge approaches, providing a deeper understanding of the evolving landscape of patient-centered care. #PrecisionMedicine #ProstateCancer #HealthcareInnovation #Pharmacy

We're honoured to have our CEO Dr Huren Sivaraj lend his expertise on the future of AI in transforming how we dose chemotherapy in this important article from American Society of Clinical Oncology (ASCO). As pioneers of AI-powered cancer care, Oncoshot shares the perspective that AI and machine learning will be pivotal in providing truly personalised care. Read this timely piece to learn about the challenges with current dosing paradigms and the vast potential of using artificial intelligence to improve patient outcomes, lower costs, and achieve precision medicine for all. Dr Sivaraj, Dr Arjun Ravishankar, and Dr Raghav Sundar MBBS, PhD provide thoughtful views on how AI-based platforms can optimise regimens to each patient's needs. We welcome discussions on the ethical application of AI in advancing oncology! https://lnkd.in/dwbrNHKx #patientoutcomes #personalizedmedicine #precisionmedicine #dosing #chemotherapy #oncology #clinicaltrials